This article provides a comprehensive guide for researchers and drug development professionals on managing the pervasive challenge of confounding by indication in observational studies.
This article provides a comprehensive framework for researchers and drug development professionals to address heterogeneity in network meta-analysis (NMA).
With a 90% failure rate in clinical drug development, often due to insufficient efficacy or unmanageable toxicity, the pharmaceutical industry is re-evaluating its lead optimization paradigms.
This article provides a comprehensive overview of quantitative evidence synthesis methods essential for robust assessment of drug safety and efficacy.
This article provides a comprehensive overview of the use of Physician Prescribing Preference (PPP) as an instrumental variable (IV) in comparative effectiveness research and pharmacoepidemiology.
This article provides a comprehensive guide for researchers and drug development professionals on navigating clinical heterogeneity and Heterogeneity of Treatment Effects (HTE) in comparative effectiveness research.
Combination therapies are a cornerstone of modern treatment for complex diseases like cancer, autoimmune disorders, and Alzheimer's, but optimizing their dosing and scheduling presents significant challenges.
This article provides a comprehensive guide for researchers and drug development professionals on designing and implementing robust real-world evidence (RWE) studies to demonstrate drug effectiveness.
This article provides a comprehensive overview of the application of propensity score (PS) methods in pharmacoepidemiology, targeting researchers and drug development professionals.
This article provides a comprehensive guide to applying Bayesian models for Mixed Treatment Comparisons (MTC), also known as Network Meta-Analysis, in biomedical and pharmaceutical research.